Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Other Accumulated Expenses (2019 - 2024)

Historic Other Accumulated Expenses for aTYR PHARMA (ATYR) over the last 6 years, with Q4 2024 value amounting to $769000.0.

  • aTYR PHARMA's Other Accumulated Expenses fell 3009.09% to $769000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $769000.0, marking a year-over-year decrease of 3009.09%. This contributed to the annual value of $769000.0 for FY2024, which is 3009.09% down from last year.
  • aTYR PHARMA's Other Accumulated Expenses amounted to $769000.0 in Q4 2024, which was down 3009.09% from $1.1 million recorded in Q4 2023.
  • aTYR PHARMA's Other Accumulated Expenses' 5-year high stood at $1.9 million during Q4 2022, with a 5-year trough of $672000.0 in Q4 2021.
  • Its 5-year average for Other Accumulated Expenses is $1.0 million, with a median of $769000.0 in 2024.
  • Per our database at Business Quant, aTYR PHARMA's Other Accumulated Expenses surged by 18720.24% in 2022 and then tumbled by 4300.52% in 2023.
  • Over the past 5 years, aTYR PHARMA's Other Accumulated Expenses (Quarter) stood at $674000.0 in 2020, then dropped by 0.3% to $672000.0 in 2021, then surged by 187.2% to $1.9 million in 2022, then tumbled by 43.01% to $1.1 million in 2023, then tumbled by 30.09% to $769000.0 in 2024.
  • Its last three reported values are $769000.0 in Q4 2024, $1.1 million for Q4 2023, and $1.9 million during Q4 2022.